Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release oral tablet for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when a continuous opioid analgesic is required. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts within the central nervous system to alleviate pain associated with several chronic conditions.

- Chronic low back pain: provides sustained relief of moderate to severe pain over a 24‑hour period. - Osteoarthritis pain: reduces pain intensity and improves functional mobility. - Neuropathic pain associated with diabetic peripheral neuropathy: helps control persistent neuropathic discomfort. - Cancer‑related chronic pain: contributes to long‑term pain control as part of multimodal therapy. - Post‑surgical chronic pain syndromes: assists in managing lingering pain after major surgical procedures.

Tapentadol Hydrochloride may cause a range of adverse reactions, from mild to serious, that should be monitored during therapy.

Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Serotonin syndrome - Allergic reactions (rash, angioedema) - Dependence or abuse potential

When prescribing Tapentadol Hydrochloride, clinicians should consider several safety aspects to minimize risk.

- Assess pain severity and opioid tolerance: ensure the patient requires a strong opioid. - Review medical history: avoid use in patients with significant respiratory disease. - Monitor for signs of misuse or dependence: educate patients on proper use. - Caution in renal or hepatic impairment: dose adjustments may be needed. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Tapentadol Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may increase respiratory depression risk. - MAO‑inhibitors: may precipitate hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may raise serotonin syndrome risk. - CYP2D6 inhibitors (e.g., quinidine): can increase tapentadol plasma levels. - Antihistamines or anticholinergics: may enhance sedation and anticholinergic effects. - Diuretics: may potentiate hypotensive effects. - Alcohol: additive central nervous system depression.